产品: HO-1 小鼠 单克隆 抗体
货号: BF8020
描述: Mouse monoclonal antibody to HO-1
应用: WB IHC IF/ICC
文献验证: WB, IHC, IF/ICC
反应: Human, Mouse
分子量: 33 kDa; 33kD(Calculated).
蛋白号: P09601

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Mouse
应用:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse
克隆:
Monoclonal [AFfirm8020]
特异性:
HO-1 Antibody detects endogenous levels of total HO-1.
偶联:
Unconjugated.
纯化:
Affinity-chromatography.
保存:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

32 kD; bK286B10; D8Wsu38e; heat shock protein 32 kD; heat shock protein 32kD; Heat shock protein; Heme oxygenase (decycling) 1; Heme oxygenase 1; Hemox; HMOX 1; Hmox; Hmox1; HMOX1_HUMAN; HO 1; HO; HO-1; HO1; Hsp32;

抗原和靶标

免疫原:

A synthesized peptide derived from human HO-1.

Uniprot:
基因/基因ID:
表达:
P09601 HMOX1_HUMAN:

Expressed at higher levels in renal cancer tissue than in normal tissue (at protein level).

序列:
MERPQPDSMPQDLSEALKEATKEVHTQAENAEFMRNFQKGQVTRDGFKLVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQSPSRAPGLRQRASNKVQDSAPVETPRGKPPLNTRSQAPLLRWVLTLSFLVATVAVGLYAM

研究背景

功能:

Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Exhibits cytoprotective effects since excess of free heme sensitizes cells to undergo apoptosis.

细胞定位:

Microsome. Endoplasmic reticulum membrane>Peripheral membrane protein>Cytoplasmic side.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Expressed at higher levels in renal cancer tissue than in normal tissue (at protein level).

蛋白家族:

Belongs to the heme oxygenase family.

研究领域

· Cellular Processes > Cell growth and death > Ferroptosis.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Metabolism > Metabolism of cofactors and vitamins > Porphyrin and chlorophyll metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Digestive system > Mineral absorption.

文献引用

1). Natural Linoleic Acid from Marine Fungus Eutypella sp. F0219 Blocks KEAP1/NRF2 Interaction and Ameliorates MASLD by Targeting FABP4. Free radical biology & medicine, 2024 (PubMed: 39299527) [IF=7.1]

2). The ferroptosis of sertoli cells inducing blood-testis barrier damage is produced by oxidative stress in cryptorchidism. Free radical biology & medicine, 2025 (PubMed: 40032029) [IF=7.1]

3). Dihydroartemisinin inhibits galectin-1-induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2-HO-1 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2025 (PubMed: 41166905) [IF=6.7]

Application: WB    Species: human    Sample: HGC-27 cells

Fig. 7. Nrf2 inhibition attenuates the ferroptosis resistance induced by galectin-1 overexpression. Western blot analyses were performed to detect the HO-1 and GPX4 expression levels in SGC-7901(A) and HGC-27 (B)cells with KD-LGALS1or OE-LGALS1 (C, D). Immunofluorescence staining was used to evaluate the expression of Nrf2, HO-1, and GPX4 in SGC-7901 (E) and HGC-27 (F) cells with OE-LGALS1 and treated with ML385 (400 × magnification). (G, H) Quantitative analysis of target protein expression across experimental groups. (I) BODIPY C11 staining was performed to assess lipid ROS levels in GC cells with OE-LGALS1 and treated with ML385 (200 × magnification). (J) Quantitative analysis of the fluorescence intensity of oxidized BODIPY across the groups. WT: Wild Type; NS: not statistically significant

Application: IF/ICC    Species: human    Sample: HGC-27 cells

Fig. 7. Nrf2 inhibition attenuates the ferroptosis resistance induced by galectin-1 overexpression. Western blot analyses were performed to detect the HO-1 and GPX4 expression levels in SGC-7901(A) and HGC-27 (B)cells with KD-LGALS1or OE-LGALS1 (C, D). Immunofluorescence staining was used to evaluate the expression of Nrf2, HO-1, and GPX4 in SGC-7901 (E) and HGC-27 (F) cells with OE-LGALS1 and treated with ML385 (400 × magnification). (G, H) Quantitative analysis of target protein expression across experimental groups. (I) BODIPY C11 staining was performed to assess lipid ROS levels in GC cells with OE-LGALS1 and treated with ML385 (200 × magnification). (J) Quantitative analysis of the fluorescence intensity of oxidized BODIPY across the groups. WT: Wild Type; NS: not statistically significant

Application: IHC    Species: Mouse    Sample:

Fig. 9. Galectin-1 activates the PI3K/Akt/Nrf2/HO-1/GPX4 signal-ing pathway to inhibit ferroptosis and promote GCPM. (A) Schematic illustration of the GCPM animal model. (B) Representative images of H&E staining, iron staining, and IHC for TfR1, FPN1, and GPX4 in the mouse PM model (400 × magnification). (C, D) Statistical analysis of the IOD of iron-stained and the IRSs of TfR1 FPN1 and GPX4 in each group. (E) Representative images of IHC for galectin-1, PI3K, p-PI3K, Akt, p-Akt, Nrf2, and HO-1 in peritoneal nodule tissues from each group (400 × magnification). (F–I) Quantitative analysis of the IRSs of target proteins across the experimental groups. WT: Wild Type; NS: not statistically significant

4). Molybdenum Nanoparticles Alleviate MC903-Induced Atopic Dermatitis-Like Symptoms in Mice by Modulating the ROS-Mediated NF-κB and Nrf2 /HO-1 Signaling Pathways. International journal of nanomedicine, 2024 (PubMed: 39220192) [IF=6.6]

5). Antioxidation and Anti-Inflammatory Activity of Prussian Blue Nanozymes to Alleviate Acetaminophen-Induced Acute Liver Injury. ACS Applied Nano Materials, 2023 [IF=5.9]

6). Promoting spinal cord injury repair by using ZnO@MOFs nanozymes functionalized hydrogel through the ROS microenvironment regulating pathway. Regenerative biomaterials, 2025 (PubMed: 41190134) [IF=5.6]

Application: IF/ICC    Species: Rat    Sample: PC12 cells

Figure 6.(A) CLSM images of GPX4 expression in PC12 cells. (B) GPX4 intensity analysis. (C) CLSM images of HO-1 expression in PC12 cells. (D) HO-1 intensity analysis. The bars are both 50 μm. (n = 3,

7). Bisphenol A induced neuronal apoptosis and enhanced autophagy in vitro through Nrf2/HO-1 and Akt/mTOR pathways. Toxicology, 2023 (PubMed: 38006930) [IF=4.8]

8). Effects of Oltipraz on the Glycolipid Metabolism and the Nrf2/HO-1 Pathway in Type 2 Diabetic Mice. Drug design, development and therapy, 2024 (PubMed: 39654602) [IF=4.7]

Application: WB    Species: Mouse    Sample:

Figure 5 OLTI showed an anti-oxidation stress and anti-apoptosis function in T2DM. (A–G) the expression of Nrf2, HO-1, NQO1, Bax, Bcl-2, Caspase-3, and Reg3g in mRNA level. (H–O) the expression of Nrf2, HO-1, NQO1, Bax, Bcl-2, Caspase-3, and Reg3g in protein level. *P

9). ROS Regulate Rotenone-induced SH-SY5Y Dopamine Neuron Death Through Ferroptosis-mediated Autophagy and Apoptosis. Molecular neurobiology, 2025 (PubMed: 40097764) [IF=4.6]

10). Oleanonic acid ameliorates mutant Aβ precursor protein-induced oxidative stress, autophagy deficits, ferroptosis, mitochondrial damage, and ER stress in vitro. Biochimica et biophysica acta. Molecular basis of disease, 2024 (PubMed: 39134286) [IF=4.2]

加载更多

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.